15495-41-7

Upstream product

• 1744-99-6 9-chloro-5-methoxy-3-nitroacridine 
• 104-94-9 4-methoxy-aniline 
• 90-04-0 2-methoxy-phenylamine 
• 1744-93-0 2-(2-methoxyanilino)-4-nitrobenzoic acid 
• 1745-01-3 5-methoxy-3-nitro-10H-acridin-9-one 

Relevant academic research and scientific papers

Synthesis and antitumor activity of 9-anilino, phenylhydrazino, and sulphonamido analogs of 2- or 4-methoxy-6-nitroacridines

Synthesis of several new 9-anilino, phenylhydrazino, and sulphonamido analogs of 2- or 4-methoxy-6-nitroacridine derivatives is described. The prepared compounds were tested for their in vitro antitumor activity against 60 human tumor cell lines by the National Cancer Institute (NCI) and showed a potential anticancer activity. Compounds 9-(phenylhydrazino)-2-methoxy-6-nitroacridine (8a) and 9-(4-chlorophenylhydrazino)-4-methoxy-6-nitroacridine (9b) exhibited a broad spectrum antitumor activity with full panel (MG-MID) median growth inhibition(GI50), of 16.1 and 10.9 μM and total growth inhibition (TGI) of 66.7 and 37.9 μM, respectively. Meanwhile, compounds 15a and 15b showed moderate selectivity toward leukemia cell lines. As a trial to explore the mode of action of their antitumor activity, the 6-nitroacridine analogs were evaluated for their inhibitory effect on major cell cycle control proteins cdc2 kinase and cdc25 phosphatase as possible molecular targets that may account for antimitotic potency. None of the tested compounds proved to exert their activity via this antimitotic mode of action.